Cargando…

First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity

Transurethral resection of the tumor (TUR-B) followed by adjuvant intravesical treatment with cytostatic drugs or Bacillus Calmette–Guérin (BCG) as standard therapy of non-muscle-invasive bladder cancer (NMIBC) is associated with a high recurrence rate of about 60–70%, considerable side effects and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruf, Peter, Bauer, Hartwig W., Schoberth, Alexandra, Kellermann, Claudia, Lindhofer, Horst
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360869/ https://www.ncbi.nlm.nih.gov/pubmed/33837852 http://dx.doi.org/10.1007/s00262-021-02930-7

Ejemplares similares

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients
por: Ruf, Peter, et al.
Publicado: (2010)

Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab(®))
por: Seimetz, Diane
Publicado: (2011)

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
por: Heiss, Markus M, et al.
Publicado: (2010)

Potent CD4(+) T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition
por: Deppisch, Nina, et al.
Publicado: (2016)

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis
por: Ströhlein, Michael A, et al.
Publicado: (2009)

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer
por: Ruf, P, et al.
Publicado: (2007)

Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
por: Ott, Marion G, et al.
Publicado: (2012)

Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model
por: Ruf, Peter, et al.
Publicado: (2012)

Review of catumaxomab in the treatment of malignant ascites
por: Sebastian, Martin
Publicado: (2010)

Palliative treatment of malignant ascites: profile of catumaxomab
por: Ammouri, Lila, et al.
Publicado: (2010)

Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
por: Knödler, Maren, et al.
Publicado: (2018)

GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2021)

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
por: Haense, N., et al.
Publicado: (2016)

Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model
por: Ivasko, Sara Marie, et al.
Publicado: (2023)

Immunological mechanisms of intravesical chitosan/interleukin-12 immunotherapy against murine bladder cancer
por: Smith, Sean G., et al.
Publicado: (2016)

Expansion microscopy with carboxylic trifunctional linkers: Expansion microscopy with carboxylic trifunctional linkers
por: Chen, Xuecheng, et al.
Publicado: (2022)

Removal of EpCAM-positive tumor cells from blood collected during major oncological surgery using the Catuvab device- a pilot study
por: Winter, Andreas, et al.
Publicado: (2021)

P18. The tumour leukocyte infiltrate is the key predictor for therapeutic response to catumaxomab therapy
por: Weiler, K, et al.
Publicado: (2014)

Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report
por: Bezan, Angelika, et al.
Publicado: (2013)

Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence
por: Zhang, Jianglei, et al.
Publicado: (2021)

Intravesical Treatments of Bladder Cancer: Review
por: Shen, Zancong, et al.
Publicado: (2008)

Intravesical therapy for urothelial carcinoma of the bladder
por: Manoharan, M.
Publicado: (2011)

Tumor Targeting, Trifunctional Dendritic Wedge
por: Dubey, Ramin, et al.
Publicado: (2014)

Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro
por: Seeber, Andreas, et al.
Publicado: (2015)

Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma
por: Ord, J J, et al.
Publicado: (2005)

Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial
por: Buhmann, Raymund, et al.
Publicado: (2013)

Long-Term Efficacy, Safety, and Tolerability of Modified Intravesical Oxybutynin Chloride for Neurogenic Bladder in Children
por: Honda, Masashi, et al.
Publicado: (2019)

Hyperthermia as Adjunct to Intravesical Chemotherapy for Bladder Cancer
por: Owusu, Richmond A., et al.
Publicado: (2013)

Intravesical immunotherapy in nonmuscle invasive bladder cancer
por: Jokisch, Jan-Friedrich, et al.
Publicado: (2015)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Intravesical Agents in the Treatment of Bladder Clots in Children
por: Della Corte, Marcello, et al.
Publicado: (2023)

Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab
por: Goéré, Diane, et al.
Publicado: (2014)

Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
por: Chung, J. Y., et al.
Publicado: (1993)

Recurrent urinary tract infections in patients with incomplete bladder emptying: is there a role for intravesical therapy?
por: Dray, Elizabeth V., et al.
Publicado: (2017)

Synthesis of trifunctional cyclo-β-tripeptide templates
por: Stein, Frank, et al.
Publicado: (2012)

Factors effecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG
por: Kashif Khan, Muhammad, et al.
Publicado: (2014)

Correlation of Male Overactive Bladder with Intravesical Prostatic Protrusion
por: Kim, Ki Hong, et al.
Publicado: (2010)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
por: To, Uyen, et al.
Publicado: (2014)

Intravesical chemotherapy in non-muscle-invasive bladder cancer
por: Porten, Sima P., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_n7j798h8fa2hkrj2e60gs1bl14